Nelson Vergel
Founder, ExcelMale.com
Curated By Nelson Vergel | ExcelMale.com | Updated June 2026
Many men in the ExcelMale community who get coronary CT angiography end up referred for an invasive catheterization, not because their arteries are clearly blocked, but because calcified plaque made the scan too hard to read. That diagnostic bottleneck has a name: calcium blooming. And a new class of CT scanner is addressing it more effectively than anything available before.
Photon-counting detector CT (PCD-CT) received its first FDA clearance in 2021. A 2025 study at a single center following 7,833 patients found it was a more accurate gatekeeper to invasive procedures than conventional CT. The implications for men on TRT who monitor their cardiovascular health are real: if you have elevated coronary calcium or have ever received an inconclusive CCTA result, this technology is worth understanding.
Conventional CT scanners use energy-integrating detectors (EIDs). X-ray photons strike the detector, are converted to light, and that light is then converted to an electrical signal. This two-step process introduces electronic noise and places a lower limit on how small each detector element can be.
Photon-counting detectors skip the light step entirely. Each incoming photon converts directly to an electrical pulse, and the detector counts individual photons while simultaneously recording the energy of each one. The result is sharper images, lower electronic noise, and - because every scan captures multi-energy data automatically - spectral information available on every acquisition without a separate scan.
Ultrahigh-resolution (UHR) imaging, defined as imaging on detector elements smaller than 0.25 mm, becomes clinically practical with this architecture. Coronary arteries are typically 2 to 4 mm in diameter. Conventional CT has always struggled at that scale, particularly when calcium is present.
Finer spatial resolution allows better delineation of vessel walls, stent struts, and the margins of calcified plaque. Reduced electronic noise enables dose savings without sacrificing image quality. Always-on spectral data lets radiologists reconstruct virtual monoenergetic images and iodine maps from any routine scan without re-scanning the patient.
Calcium blooming is the primary reason conventional CCTA becomes unreliable in men with high CAC scores. When a dense calcified plaque sits near a coronary artery, conventional detectors spread the calcium signal outward, making the plaque appear larger than it is and the vessel lumen appear narrower. The result is stenosis overestimation, which leads radiologists and cardiologists toward unnecessary invasive procedures.
PCD-CT's UHR mode reduces this artifact by imaging at sub-millimeter detector resolution, which better defines the true calcium boundary. The benefit is concentrated in calcified disease. For mixed or non-calcified plaques, the advantage is minimal because calcium blooming was not the limiting factor in those cases.
A 2026 study from Brigham and Women's Hospital (Shiyovich et al., JACC Advances) used PCD-CT to evaluate asymptomatic patients with extreme coronary calcium scores above 1,000 Agatston units - a population where conventional CT typically produces images too degraded to read. The technology could delineate vessel lumen in cases that conventional CT would have sent directly to invasive catheterization.
The small pixel effect is the mechanism behind dose savings. Because PCD-CT acquires data at ultrahigh resolution, that data can be reconstructed at standard resolution - and in doing so, the reconstruction step reduces image noise substantially. Fix Martinez and colleagues (European Radiology, 2024) documented potential radiation reductions of 30 to 80%, depending on protocol.
Virtual monoenergetic images at low energy settings (around 40 keV) also amplify iodine attenuation, allowing contrast volume reductions of 25 to 57% compared to conventional CCTA. For men with borderline kidney function - common in older men with metabolic syndrome or long-standing hypertension - that reduced contrast load makes coronary CTA feasible in cases where it might otherwise be deferred.
This is where the clinical evidence is clearest.
Sakai and colleagues (J Am Coll Cardiol, 2025) followed 7,833 consecutive patients who underwent coronary CTA at a single center: 3,876 on PCD-CT and 3,957 on conventional EID-CT. Patients scanned with PCD-CT were referred to invasive coronary angiography less frequently. Among those who were referred, the revascularization rate was higher - meaning fewer patients underwent an invasive procedure without finding anything that needed treatment.
A 2025 propensity score-matched study in the Journal of Clinical Medicine (Nakashima et al., 820 patients, 410 per group) quantified this more precisely. Among patients referred for invasive angiography after conventional CT, 44.1% were revascularized. Among those referred after PCD-CT, 62.5% were revascularized. The rate of invasive angiography without revascularization dropped from 8.0% to 3.7%. Specificity for diagnosing significant stenosis improved from 0.74 with conventional CT to 0.81 with PCD-CT.
PCD-CT acts as a better gatekeeper. It sends fewer people to the catheterization laboratory. When it does refer someone, that referral is more likely to be accurate.
Image quality data supports this outcome. In the first-in-human coronary CTA study using PCD-CT (Si-Mohamed et al., Radiology, 2022), three independent radiologists scored overall image quality higher on PCD-CT than on energy-integrating dual-layer CT - median 5 vs. 4 on a five-point scale - with the most pronounced improvement in visualization of small distal coronary branches.
Not every patient getting a cardiac CT scan needs PCD-CT, and the evidence does not show uniform advantage across all clinical presentations.
The cases where PCD-CT provides the clearest benefit:
Where the advantage is smaller: men with low coronary calcium and primarily non-calcified plaque. Conventional CCTA already performs well in that population. Calcium blooming is not the limiting factor, and PCD-CT's main imaging improvements do not apply.
The technology performs as the clinical evidence describes. The barriers are practical, not fundamental.
Most men on TRT getting baseline cardiovascular monitoring do not need PCD-CT as a starting point. A standard CAC score is the appropriate first step: widely available, inexpensive, and backed by decades of risk stratification data. For men with CAC scores below 100, conventional monitoring is appropriate.
The decision changes when CAC is above 400 and further imaging is warranted, when a prior CCTA came back non-diagnostic because of calcium artifacts, or when a cardiologist is considering invasive catheterization primarily to clarify what conventional CT could not resolve. In those situations, asking whether PCD-CT is available - and finding the nearest academic center that has it - is reasonable before scheduling conventional CCTA or accepting an invasive referral.
A CAC score scan is a non-contrast CT that quantifies calcified plaque in the coronary arteries. It tells you how much calcium is present; it does not show whether any given plaque is narrowing blood flow. It is primarily a risk stratification tool.
Coronary CT angiography (CCTA) adds iodinated contrast and produces images of the coronary artery lumen, allowing assessment of whether plaques are actually obstructing flow. CCTA provides more clinical detail but requires contrast injection, costs more, and is more technically demanding, especially when calcium is heavy. PCD-CT improves the quality of CCTA; it is a different CT hardware technology, not a different type of test.
Coronary CTA itself remains inconsistently covered by insurance despite being in clinical guidelines for over 20 years. PCD-CT does not create a separate billing code. A coronary CTA performed on a PCD-CT scanner is billed the same way as one on conventional CT. The imaging center absorbs the higher equipment cost. If coverage is uncertain, contact the imaging center directly about self-pay options.
If your CAC score is above 400 and your cardiologist recommends coronary CTA, asking whether PCD-CT is available is reasonable. The clinical evidence (JACC 2025; JCM 2025) shows a meaningful reduction in false-positive referrals to invasive angiography in patients with heavy calcification. If conventional CCTA has already returned indeterminate results because of calcium, PCD-CT at a referral center is the logical next step before accepting diagnostic uncertainty or proceeding to catheterization.
One practical detail that most discussions of cardiac CT miss: an indeterminate coronary CT result caused by calcium blooming is not the end of the road. Before 2021, that result often led directly to invasive catheterization by default. PCD-CT changes that pathway at centers where it exists. For men in their 50s and 60s with years of TRT history, significant metabolic risk factors, and a calcium score that warrants further evaluation, knowing which centers have PCD-CT and asking about it before scheduling conventional CCTA in the setting of heavy coronary calcium could prevent an invasive procedure and the recovery that comes with it. The evidence base is real enough to make it worth the question.
For related reading, explore the cardiovascular health and imaging discussions in the ExcelMale Health and Wellness subforum, including our guide on coronary calcium scoring and Dr. Budoff's explanation of what cardiac CT actually reveals about plaque.
Many men in the ExcelMale community who get coronary CT angiography end up referred for an invasive catheterization, not because their arteries are clearly blocked, but because calcified plaque made the scan too hard to read. That diagnostic bottleneck has a name: calcium blooming. And a new class of CT scanner is addressing it more effectively than anything available before.
Photon-counting detector CT (PCD-CT) received its first FDA clearance in 2021. A 2025 study at a single center following 7,833 patients found it was a more accurate gatekeeper to invasive procedures than conventional CT. The implications for men on TRT who monitor their cardiovascular health are real: if you have elevated coronary calcium or have ever received an inconclusive CCTA result, this technology is worth understanding.
How Does Photon-Counting CT Work Differently From Conventional Coronary CT Angiography?
Conventional CT scanners use energy-integrating detectors (EIDs). X-ray photons strike the detector, are converted to light, and that light is then converted to an electrical signal. This two-step process introduces electronic noise and places a lower limit on how small each detector element can be.
Photon-counting detectors skip the light step entirely. Each incoming photon converts directly to an electrical pulse, and the detector counts individual photons while simultaneously recording the energy of each one. The result is sharper images, lower electronic noise, and - because every scan captures multi-energy data automatically - spectral information available on every acquisition without a separate scan.
Ultrahigh-resolution (UHR) imaging, defined as imaging on detector elements smaller than 0.25 mm, becomes clinically practical with this architecture. Coronary arteries are typically 2 to 4 mm in diameter. Conventional CT has always struggled at that scale, particularly when calcium is present.
Finer spatial resolution allows better delineation of vessel walls, stent struts, and the margins of calcified plaque. Reduced electronic noise enables dose savings without sacrificing image quality. Always-on spectral data lets radiologists reconstruct virtual monoenergetic images and iodine maps from any routine scan without re-scanning the patient.
What Does Photon-Counting CT Actually Improve for Coronary Artery Imaging?
Does Photon-Counting CT Reduce Calcium Blooming?
Calcium blooming is the primary reason conventional CCTA becomes unreliable in men with high CAC scores. When a dense calcified plaque sits near a coronary artery, conventional detectors spread the calcium signal outward, making the plaque appear larger than it is and the vessel lumen appear narrower. The result is stenosis overestimation, which leads radiologists and cardiologists toward unnecessary invasive procedures.
PCD-CT's UHR mode reduces this artifact by imaging at sub-millimeter detector resolution, which better defines the true calcium boundary. The benefit is concentrated in calcified disease. For mixed or non-calcified plaques, the advantage is minimal because calcium blooming was not the limiting factor in those cases.
A 2026 study from Brigham and Women's Hospital (Shiyovich et al., JACC Advances) used PCD-CT to evaluate asymptomatic patients with extreme coronary calcium scores above 1,000 Agatston units - a population where conventional CT typically produces images too degraded to read. The technology could delineate vessel lumen in cases that conventional CT would have sent directly to invasive catheterization.
How Much Does Photon-Counting CT Reduce Radiation Dose?
The small pixel effect is the mechanism behind dose savings. Because PCD-CT acquires data at ultrahigh resolution, that data can be reconstructed at standard resolution - and in doing so, the reconstruction step reduces image noise substantially. Fix Martinez and colleagues (European Radiology, 2024) documented potential radiation reductions of 30 to 80%, depending on protocol.
Virtual monoenergetic images at low energy settings (around 40 keV) also amplify iodine attenuation, allowing contrast volume reductions of 25 to 57% compared to conventional CCTA. For men with borderline kidney function - common in older men with metabolic syndrome or long-standing hypertension - that reduced contrast load makes coronary CTA feasible in cases where it might otherwise be deferred.
Does Photon-Counting CT Reduce Unnecessary Cardiac Catheterizations?
This is where the clinical evidence is clearest.
Sakai and colleagues (J Am Coll Cardiol, 2025) followed 7,833 consecutive patients who underwent coronary CTA at a single center: 3,876 on PCD-CT and 3,957 on conventional EID-CT. Patients scanned with PCD-CT were referred to invasive coronary angiography less frequently. Among those who were referred, the revascularization rate was higher - meaning fewer patients underwent an invasive procedure without finding anything that needed treatment.
A 2025 propensity score-matched study in the Journal of Clinical Medicine (Nakashima et al., 820 patients, 410 per group) quantified this more precisely. Among patients referred for invasive angiography after conventional CT, 44.1% were revascularized. Among those referred after PCD-CT, 62.5% were revascularized. The rate of invasive angiography without revascularization dropped from 8.0% to 3.7%. Specificity for diagnosing significant stenosis improved from 0.74 with conventional CT to 0.81 with PCD-CT.
PCD-CT acts as a better gatekeeper. It sends fewer people to the catheterization laboratory. When it does refer someone, that referral is more likely to be accurate.
Image quality data supports this outcome. In the first-in-human coronary CTA study using PCD-CT (Si-Mohamed et al., Radiology, 2022), three independent radiologists scored overall image quality higher on PCD-CT than on energy-integrating dual-layer CT - median 5 vs. 4 on a five-point scale - with the most pronounced improvement in visualization of small distal coronary branches.
Who Is Most Likely to Benefit From Photon-Counting CT Instead of Standard CCTA?
Not every patient getting a cardiac CT scan needs PCD-CT, and the evidence does not show uniform advantage across all clinical presentations.
The cases where PCD-CT provides the clearest benefit:
- High coronary calcium burden. A CAC score above 400 is the threshold at which conventional CCTA becomes technically challenging in most guidelines. Calcium blooming worsens as calcium burden rises. A 2023 accuracy study (Hagar et al., Radiology) confirmed that UHR PCD-CT delivers excellent diagnostic performance in high-risk calcified populations where conventional CT underperforms.
- Prior indeterminate CCTA. If a previous scan came back non-diagnostic because of calcium artifacts, PCD-CT is the logical next imaging step before invasive catheterization.
- Coronary stent assessment. UHR mode improves in-stent lumen visualization, a historically difficult imaging problem with conventional CT that often led to invasive follow-up. Kravchenko and colleagues (Echocardiography, 2025) reviewed this advantage in detail.
- Borderline kidney function. The 25 to 57% reduction in required contrast volume makes coronary CTA feasible for patients who might otherwise be excluded due to elevated creatinine.
Where the advantage is smaller: men with low coronary calcium and primarily non-calcified plaque. Conventional CCTA already performs well in that population. Calcium blooming is not the limiting factor, and PCD-CT's main imaging improvements do not apply.
What Are the Current Limitations and Access Barriers for Photon-Counting CT?
The technology performs as the clinical evidence describes. The barriers are practical, not fundamental.
- Access and cost. As of 2026, commercial PCD-CT hardware comes from a small number of vendors. Deployment is concentrated in academic medical centers and major cardiovascular referral hospitals. Direct-to-consumer cardiac imaging networks have not broadly adopted the technology. If you want a PCD-CT scan, you likely need to seek out a major academic cardiology program.
- Two detector physics trade-offs persist. Cross-talk occurs when a single photon generates a signal in more than one adjacent detector element, reducing spatial and energy resolution. Pile-up occurs when photon arrival rates exceed the detector's processing speed. Both are known engineering challenges, and hardware generations are narrowing them.
- Protocol standardization is still developing. Since 2021, the evidence base has grown rapidly but without established consensus on acquisition parameters, reconstruction algorithms, or reporting standards. Different centers may use different approaches, which limits direct comparison of published results.
- Radiomics reproducibility. Quantitative plaque texture analysis shows reduced reproducibility between PCD-CT and conventional CT systems. For standard clinical diagnosis, this is minor. For research that pools data across scanner types, it is a real limitation.
Frequently Asked Questions
Should Men on TRT Specifically Ask About Photon-Counting CT for Cardiovascular Monitoring?
Most men on TRT getting baseline cardiovascular monitoring do not need PCD-CT as a starting point. A standard CAC score is the appropriate first step: widely available, inexpensive, and backed by decades of risk stratification data. For men with CAC scores below 100, conventional monitoring is appropriate.
The decision changes when CAC is above 400 and further imaging is warranted, when a prior CCTA came back non-diagnostic because of calcium artifacts, or when a cardiologist is considering invasive catheterization primarily to clarify what conventional CT could not resolve. In those situations, asking whether PCD-CT is available - and finding the nearest academic center that has it - is reasonable before scheduling conventional CCTA or accepting an invasive referral.
What Is the Practical Difference Between a CAC Score and a Coronary CT Angiography?
A CAC score scan is a non-contrast CT that quantifies calcified plaque in the coronary arteries. It tells you how much calcium is present; it does not show whether any given plaque is narrowing blood flow. It is primarily a risk stratification tool.
Coronary CT angiography (CCTA) adds iodinated contrast and produces images of the coronary artery lumen, allowing assessment of whether plaques are actually obstructing flow. CCTA provides more clinical detail but requires contrast injection, costs more, and is more technically demanding, especially when calcium is heavy. PCD-CT improves the quality of CCTA; it is a different CT hardware technology, not a different type of test.
Is Photon-Counting CT Covered by Insurance?
Coronary CTA itself remains inconsistently covered by insurance despite being in clinical guidelines for over 20 years. PCD-CT does not create a separate billing code. A coronary CTA performed on a PCD-CT scanner is billed the same way as one on conventional CT. The imaging center absorbs the higher equipment cost. If coverage is uncertain, contact the imaging center directly about self-pay options.
If My Calcium Score Is Above 400, Should I Request PCD-CT?
If your CAC score is above 400 and your cardiologist recommends coronary CTA, asking whether PCD-CT is available is reasonable. The clinical evidence (JACC 2025; JCM 2025) shows a meaningful reduction in false-positive referrals to invasive angiography in patients with heavy calcification. If conventional CCTA has already returned indeterminate results because of calcium, PCD-CT at a referral center is the logical next step before accepting diagnostic uncertainty or proceeding to catheterization.
Conclusion: What This Means for Cardiovascular Monitoring on TRT
One practical detail that most discussions of cardiac CT miss: an indeterminate coronary CT result caused by calcium blooming is not the end of the road. Before 2021, that result often led directly to invasive catheterization by default. PCD-CT changes that pathway at centers where it exists. For men in their 50s and 60s with years of TRT history, significant metabolic risk factors, and a calcium score that warrants further evaluation, knowing which centers have PCD-CT and asking about it before scheduling conventional CCTA in the setting of heavy coronary calcium could prevent an invasive procedure and the recovery that comes with it. The evidence base is real enough to make it worth the question.
For related reading, explore the cardiovascular health and imaging discussions in the ExcelMale Health and Wellness subforum, including our guide on coronary calcium scoring and Dr. Budoff's explanation of what cardiac CT actually reveals about plaque.
Related ExcelMale Forum Discussions
- Why You Need a Calcium Score to Know Your Real Heart Risk | Dr. Matthew Budoff - Dr. Matthew Budoff explains why CAC scoring predicts cardiovascular events more reliably than cholesterol testing alone, when to escalate to coronary CTA, and why plaque regression is possible with targeted treatment.
- What a Cardiac CT Actually Shows: Explained by a Doctor Who Has Read 100,000 Scans - Dr. Budoff walks through exactly what a coronary CTA reveals, how plaque and blockages are classified, and why insurance still fails to cover it consistently for many patients.
- Pictures Are Worth a 1000 Words: Role of Imaging in CV Risk Assessment - Community synthesis of the case for direct coronary imaging over standard lab-based cardiovascular risk scores, with research links and clinical discussion.
- Repatha (Evolocumab) Effects on Coronary Artery Calcium (CAC) Scoring and CCTA - Detailed review of PCSK9 inhibitor effects on coronary calcium progression as measured by serial CCTA, including the GLAGOV trial data and Nelson Vergel's personal protocol experience.
- How Does Testosterone Therapy Affect Your Cholesterol and Lipid Profile? - Comprehensive guide covering TRT's effects on LDL, HDL, ApoB, and Lp(a), with discussion of CAC scoring as the preferred direct plaque assessment tool for men on testosterone therapy.
- TRT and Cardiovascular Disease - Detailed review of clinical trial evidence on TRT and cardiovascular outcomes, including studies that used CCTA and coronary calcium scoring to track plaque progression directly.
- My CAC Calcium Score Is High - Should I Take Vitamin K? - Community discussion of high coronary calcium scores and the important distinction between calcified and non-calcified plaque burden, with expert and member perspectives on next steps.
- TRT and Cardiovascular Risk: TRAVERSE with Caution - Critical analysis of the TRAVERSE trial and its limitations for predicting cardiovascular outcomes at physiologic and supraphysiologic TRT dosing levels.
- Anyone Taking PCSK9 Inhibitors (i.e. Repatha)? - Member experiences with evolocumab and alirocumab, including real-world coronary calcium score data before and after treatment.
- Waist-to-Hip Ratio on TRT Predicts Non-Calcified Plaque Volume - Research data from the T Trials cardiovascular arm showing that body composition predicts non-calcified plaque progression during TRT, independent of testosterone levels.
Key References
- Sakai K, Shin D, Singh M, et al. Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease. J Am Coll Cardiol. 2025;85(4):339-348. DOI: 10.1016/j.jacc.2024.10.069
- Nakashima M, Miyoshi T, Hara S, et al. Photon-Counting CT Enhances Diagnostic Accuracy in Stable Coronary Artery Disease: A Comparative Study with Conventional CT. J Clin Med. 2025;14(17):6049. DOI: 10.3390/jcm14176049
- Si-Mohamed SA, Boccalini S, Lacombe H, et al. Coronary CT Angiography with Photon-Counting CT: First-In-Human Results. Radiology. 2022;303(2):303-313. DOI: 10.1148/radiol.211780
- Hagar MT, Soschynski M, Saffar R, et al. Accuracy of Ultrahigh-Resolution Photon-Counting CT for Detecting Coronary Artery Disease in a High-Risk Population. Radiology. 2023;307(5):e223305. DOI: 10.1148/radiol.223305
- Halfmann MC, Bockius S, Emrich T, et al. Ultrahigh-Spatial-Resolution Photon-Counting Detector CT Angiography of Coronary Artery Disease for Stenosis Assessment. Radiology. 2024. DOI: 10.1148/radiol.231956
- Kravchenko D, Hagar MT, Vecsey-Nagy M, et al. Value of Ultrahigh-Resolution Photon-Counting Detector Computed Tomography in Cardiac Imaging. Echocardiography. 2025;42(2):e70100. DOI: 10.1111/echo.70100
- Fix Martinez M, Klein L, Maier J, et al. Potential Radiation Dose Reduction in Clinical Photon-Counting CT by the Small Pixel Effect. Eur Radiol. 2024;34:4484-4491. DOI: 10.1007/s00330-023-10499-1
- Shiyovich A, Blair CV, Aun JA, et al. Photon-Counting Coronary CT Angiography in Asymptomatic Patients With Extreme Coronary Artery Calcium Score. JACC Advances. 2026. DOI: 10.1016/j.jacadv.2025.102553
- Meloni A, Maffei E, Cademartiri F, et al. Technical Principles, Benefits, Challenges, and Applications of Photon Counting CT in Coronary Imaging: A Narrative Review. Cardiovasc Diagn Ther. 2024;14(4):698-724. DOI: 10.21037/cdt-24-52
- Szilveszter B, Varga-Szemes A, Pourmorteza A, Schwartz FR. Editorial: Photon Counting CT Technology in Cardiovascular Imaging. Front Cardiovasc Med. 2025. DOI: 10.3389/fcvm.2025.1641175
